Last reviewed · How we verify
A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects
This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.
Details
| Lead sponsor | Merck Sharp & Dohme LLC |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 42 |
| Start date | 2009-02 |
| Completion | 2009-03 |
Conditions
- Chemotherapy-Induced Nausea and Vomiting
Interventions
- aprepitant 165 mg
- Comparator: aprepitant 185 mg
- Comparator: fosaprepitant 150 mg
- Comparator: aprepitant with food
Primary outcomes
- Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg — Through 72 Hours Postdose
- Peak Plasma Concentration (Cmax) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg. — Through 72 Hours Postdose